S&P 500   5,068.66 (-0.02%)
DOW   38,904.56 (-0.42%)
QQQ   436.72 (+0.04%)
AAPL   180.87 (-0.16%)
MSFT   405.66 (-0.46%)
META   483.77 (+0.42%)
GOOGL   138.08 (+0.37%)
AMZN   174.06 (-0.38%)
TSLA   202.72 (+1.66%)
NVDA   786.33 (-0.58%)
NIO   5.76 (+1.95%)
AMD   176.74 (+0.41%)
BABA   77.41 (+1.18%)
T   16.64 (+0.24%)
F   12.07 (+1.00%)
MU   91.03 (+1.75%)
CGC   3.55 (+2.31%)
GE   153.88 (-0.58%)
DIS   108.41 (+0.68%)
AMC   4.70 (+5.62%)
PFE   26.99 (-0.70%)
PYPL   59.75 (+0.71%)
XOM   104.46 (+0.20%)
S&P 500   5,068.66 (-0.02%)
DOW   38,904.56 (-0.42%)
QQQ   436.72 (+0.04%)
AAPL   180.87 (-0.16%)
MSFT   405.66 (-0.46%)
META   483.77 (+0.42%)
GOOGL   138.08 (+0.37%)
AMZN   174.06 (-0.38%)
TSLA   202.72 (+1.66%)
NVDA   786.33 (-0.58%)
NIO   5.76 (+1.95%)
AMD   176.74 (+0.41%)
BABA   77.41 (+1.18%)
T   16.64 (+0.24%)
F   12.07 (+1.00%)
MU   91.03 (+1.75%)
CGC   3.55 (+2.31%)
GE   153.88 (-0.58%)
DIS   108.41 (+0.68%)
AMC   4.70 (+5.62%)
PFE   26.99 (-0.70%)
PYPL   59.75 (+0.71%)
XOM   104.46 (+0.20%)
S&P 500   5,068.66 (-0.02%)
DOW   38,904.56 (-0.42%)
QQQ   436.72 (+0.04%)
AAPL   180.87 (-0.16%)
MSFT   405.66 (-0.46%)
META   483.77 (+0.42%)
GOOGL   138.08 (+0.37%)
AMZN   174.06 (-0.38%)
TSLA   202.72 (+1.66%)
NVDA   786.33 (-0.58%)
NIO   5.76 (+1.95%)
AMD   176.74 (+0.41%)
BABA   77.41 (+1.18%)
T   16.64 (+0.24%)
F   12.07 (+1.00%)
MU   91.03 (+1.75%)
CGC   3.55 (+2.31%)
GE   153.88 (-0.58%)
DIS   108.41 (+0.68%)
AMC   4.70 (+5.62%)
PFE   26.99 (-0.70%)
PYPL   59.75 (+0.71%)
XOM   104.46 (+0.20%)
S&P 500   5,068.66 (-0.02%)
DOW   38,904.56 (-0.42%)
QQQ   436.72 (+0.04%)
AAPL   180.87 (-0.16%)
MSFT   405.66 (-0.46%)
META   483.77 (+0.42%)
GOOGL   138.08 (+0.37%)
AMZN   174.06 (-0.38%)
TSLA   202.72 (+1.66%)
NVDA   786.33 (-0.58%)
NIO   5.76 (+1.95%)
AMD   176.74 (+0.41%)
BABA   77.41 (+1.18%)
T   16.64 (+0.24%)
F   12.07 (+1.00%)
MU   91.03 (+1.75%)
CGC   3.55 (+2.31%)
GE   153.88 (-0.58%)
DIS   108.41 (+0.68%)
AMC   4.70 (+5.62%)
PFE   26.99 (-0.70%)
PYPL   59.75 (+0.71%)
XOM   104.46 (+0.20%)
NASDAQ:PRTA

Prothena (PRTA) Stock Price, News & Analysis

$29.42
+1.24 (+4.40%)
(As of 11:51 AM ET)
Today's Range
$28.35
$29.49
50-Day Range
$25.05
$40.66
52-Week Range
$24.28
$79.65
Volume
146,952 shs
Average Volume
939,713 shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.89

Prothena MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
141.4% Upside
$69.63 Price Target
Short Interest
Healthy
10.70% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Prothena in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$525,950 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.98) to ($4.00) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.04 out of 5 stars

Medical Sector

180th out of 943 stocks

Pharmaceutical Preparations Industry

73rd out of 427 stocks


PRTA stock logo

About Prothena Stock (NASDAQ:PRTA)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease and other related synucleinopathies; NNC6019 that completed Phase I clinical trial for the treatment of ATTR amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease, as well as TDP-43 and PRX019 for the treatment of Alzheimer's disease and other neurodegenerative diseases. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Stock Price History

PRTA Stock News Headlines

Energy Storage Trend Ignites Frenzy Over Vanadium Supply
As the world shifts to renewables such as wind and solar, how will we store all this energy? Vanadium batteries are the breakthrough that some experts predict will be the future of grid-scale energy storage. The problem is, only 5% of vanadium is mined in the U.S. - and China and Russia have a stranglehold on our supply.
Prothena (NASDAQ:PRTA) Stock Rating Lowered by StockNews.com
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
JMP Securities Boosts Prothena (NASDAQ:PRTA) Price Target to $85.00
PRTA Mar 2024 105.000 call
Prothena Full Year 2023 Earnings: Beats Expectations
RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)
Decoding 6 Analyst Evaluations For Prothena Corp
Earnings Outlook For Prothena Corp
Navigating 5 Analyst Ratings For Prothena Corp
See More Headlines
Receive PRTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
2/27/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTA
Employees
127
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$69.63
High Stock Price Target
$90.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+142.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
9 Analysts

Profitability

Net Income
$-147,030,000.00
Net Margins
-160.91%
Pretax Margin
-175.64%

Debt

Sales & Book Value

Annual Sales
$91.37 million
Book Value
$10.46 per share

Miscellaneous

Free Float
38,571,000
Market Cap
$1.55 billion
Optionable
Optionable
Beta
0.25
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report














PRTA Stock Analysis - Frequently Asked Questions

Should I buy or sell Prothena stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PRTA shares.
View PRTA analyst ratings
or view top-rated stocks.

What is Prothena's stock price target for 2024?

9 brokers have issued 12-month price targets for Prothena's stock. Their PRTA share price targets range from $35.00 to $90.00. On average, they anticipate the company's stock price to reach $69.63 in the next twelve months. This suggests a possible upside of 141.4% from the stock's current price.
View analysts price targets for PRTA
or view top-rated stocks among Wall Street analysts.

How have PRTA shares performed in 2024?

Prothena's stock was trading at $36.34 at the beginning of 2024. Since then, PRTA stock has decreased by 20.6% and is now trading at $28.84.
View the best growth stocks for 2024 here
.

Are investors shorting Prothena?

Prothena saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 5,750,000 shares, a drop of 8.1% from the January 15th total of 6,260,000 shares. Based on an average trading volume of 845,900 shares, the short-interest ratio is presently 6.8 days.
View Prothena's Short Interest
.

When is Prothena's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our PRTA earnings forecast
.

How were Prothena's earnings last quarter?

Prothena Co. plc (NASDAQ:PRTA) issued its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.23) by $0.03. The biotechnology company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $2.15 million. Prothena had a negative trailing twelve-month return on equity of 24.84% and a negative net margin of 160.91%. The company's revenue was down 99.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.12 earnings per share.

What other stocks do shareholders of Prothena own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prothena investors own include Cara Therapeutics (CARA), Actinium Pharmaceuticals (ATNM), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT), BioLineRx (BLRX), Gilead Sciences (GILD), Exelixis (EXEL) and ACADIA Pharmaceuticals (ACAD).

Who are Prothena's major shareholders?

Prothena's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (7.90%), Price T Rowe Associates Inc. MD (7.90%), Palo Alto Investors LP (3.09%), First Light Asset Management LLC (2.03%), Vanguard Group Inc. (1.99%) and Dimensional Fund Advisors LP (1.62%). Insiders that own company stock include Brandon S Smith, Carol D Karp, Carol D Karp, Christopher S Henney, Christopher S Henney, Dennis J Selkoe, Dennis J Selkoe, Ecor1 Capital, Llc, Gene G Kinney, Hideki Garren, Karin L Walker, Karin L Walker, Lars Ekman, Michael J Malecek, Michael J Malecek, Richard T Collier, Shane Cooke, Tran Nguyen, Wagner M Zago and Wagner M Zago.
View institutional ownership trends
.

How do I buy shares of Prothena?

Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRTA) was last updated on 2/27/2024 by MarketBeat.com Staff